Information about SaveRxCanada.to
List of countries where we can ship Rimonabant:
Latest news releases on Rimonabant:
Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1 and was the first drug approved in that class.
Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world.
Rimonabant has been reported to cause partial seizures in a patient with a history of generalized epilepsy [115 A]. A 52-year-old obese man with hypertension, diabetes mellitus, and a history of absences and two generalized tonic–clonic seizures at ages 4–15 years, but who had been seizure free for over 20 years took rimonabant 20 mg/day and 2 months later started to have nocturnal partial ...
Sanofi-Aventis has withdrawn rimonabant from the market globally and it is no longer under development. 1 Acomplia was officially withdrawn by the European Medicines Agency (EMEA) in January 2009 due to the risks of dangerous psychological side effects, including suicidality. Previously, the EMEA had suspended Acomplia from the UK market in 2008 because the agency felt the benefits did not ...
Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil.
1. Braz J Psychiatry. 2009 Jun;31(2):145-53. The psychiatric side-effects of rimonabant. Moreira FA(1), Crippa JA. Author information: (1)Department of Pharmacology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. OBJECTIVE: Experimental evidence has suggested that drugs that enhance cannabinoid type-1 (CB1) receptor activity may induce ...
Rimonabant is the first of a new class of selective cannabinoid receptor-1 blockers. It reduces the overactivity of the endocannabinoid system, improving lipid and glucose metabolism and regulating food intake and energy balance. In four randomised, double-blind clinical trials in overweight or obese adults with or without type 2 diabetes and/or dyslipidaemia, oral rimonabant 20mg once daily ...
Rimonabant (SR141716) is the first selective and orally active antagonist of the central brain cannabinoid receptor (CB1) with IC50 with 13.6 nM and EC50 with 17.3 nM in hCB1 transfected HEK 293 membrane.Find all the information about Rimonabant (SR141716) for cell signaling research.
Rimonabant (conocido también como SR141716), [n 1] es un inhibidor del apetito que actualmente se encuentra fuera del mercado en gran parte del mundo. Este es un antagonista selectivo del receptor cannabinoide CB1.  Su principal efecto es la reducción del apetito.. Rimonabant fue el primer bloqueador del receptor selectivo CB1 en ser aprobado en el mundo.
リモナバン（リモナバント, 英語: Rimonabant, SR141716）は、選択的な カンナビノイド受容体タイプ1 （英語版） の拮抗薬で、食欲 抑制剤または抗肥満薬 である。 かつての製品名はアコンプリア（Acomplia）やスリモナ（Slimona）。